Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

ated in order to integrate the virus in the panoply of agents used for sarcoma treatment."

"These results are consistent with what we observed on an interim basis when we reported data on the first 16 patients back in June 2008," said Dr. Brad Thompson, President and CEO of Oncolytics. "It is encouraging that we are observing stable disease in a range of sarcomas and the clinical benefit is not isolated to any specific type."

A copy of the poster will be available on the Oncolytics website today.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at the CTOS meeting with respect to REOLYSIN; the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2009 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actua
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 Knowledgent , ... paper that explores the potential of big data analytics ... paper was developed to help life sciences and healthcare ... data to gain critical business insights. , The life ... of data driven by patient profiling, compliance and regulatory ...
(Date:5/21/2015)... 21, 2015 Seventh Wave Laboratories, a ... efficacy of pharmaceutical products and medical devices, announced the ... 63043, a 50,000 sq. ft. building more than three ... strategic growth. Facility renovations will begin immediately and the ... will occur in September. , “We are excited ...
(Date:5/21/2015)...  Prima Biomed Ltd. (NASDAQ: PBMD ) a ... a leader in the development of immunotherapeutic products for ... CVac data from the Phase II CAN-003 ovarian cancer ... clinically meaningful improvement in Overall Survival ("OS") over standard ... In the group of second remission patients (n=20), the ...
(Date:5/21/2015)... , May 21, 2015 ... inner feelings - and those of others. Being able ... senses. Analyze and read people to anticipate their thoughts ... your deepest emotions and feelings to create unique abstract ... of responsive games. Get inside a first-person-shooter as it ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2
... March 3 Collexis Holdings Inc.,(OTC Bulletin Board: ... discovery software, announced today the launch of the ... profiles of 38 institutions and,their more than 60,000 ... clients who are also winners of the Clinical ...
... concerted, nationwide effort to,encourage and strengthen collaboration between ... a powerful team for improved patient safety,-- the ... Patient,Compact during Patient Safety Awareness Week, March 8-14, ... http://www.newscom.com/cgi-bin/prnh/20080307/AQF053LOGO ) , The ...
... Following the,completion of the Phase II clinical development of ... end of Phase,II meeting with the FDA to discuss ... there was an open and highly constructive discussion with ... the first ever formal discussions with the,agency to license ...
Cached Biology Technology:Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform 2Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform 3NPSF Issues New Universal Patient Compact During Patient Safety Awareness Week 2NPSF Issues New Universal Patient Compact During Patient Safety Awareness Week 3Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 2Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 3
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/19/2015)... May 19, 2015  Technology is rapidly advancing, outpacing ... in the cloud. Passwords and their management are soon ... and standards-based specifications such as those developed by the ... of passwords presents for BYOD, COPE, IoT, and mobile ... identity protocol. In response to the ...
(Date:5/14/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ... Sensors Market in Smart Mobile Devices " report ... 2014 was a watershed year for fingerprint sensors in ... Pay,. Apple gave fingerprint sensors a raison d,etre in ... sensors are a must-have feature in flagship smartphones. ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... of the public divided about climate change because they ... more basic science and were more proficient in technical ... study published today online in the journal Nature ... questions is no. Indeed, as members of the public ...
... it,s hard to see how a common house sparrow and a ... a bird that weighs less than an ounce, and the other ... and tipped the scales at more than eight tons. ... more closely related than many believed. A new study, led by ...
... was associated with higher mortality for eggs and hatchlings of ... worsened by continuing global climate change, according to research published ... . The El Nio Southern Oscillation brought dryer, warmer ... sites in the area. The researchers, led by Pilar Tomillo ...
Cached Biology News:Yale study concludes public apathy over climate change unrelated to science literacy 2Timing is everything 2Timing is everything 3Timing is everything 4
Dako Target Retrieval Solution, Citrate pH 6 (x 10) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
... data acquisition interface. All the functionality of ... processor, increased memory and more available channels ... also inlcudes an option for programmable front-end ... 16 to 48 waveform inputs and from ...
... to off-white solid. Increases the expression of glutathione ... in H 2 O. Unstable in aqueous ... EK7713840, CAS 3211-76-5, M.W. 196.1. References: ... and Junod, A.F. 1995. Biochem. J. ...
... designed to provide a thin film-like barrier when a ... This barrier creates the proper surface tension to ... the slide. PAP Pen contains a special formulation ... can be removed, if desired, by xylene after the ...
Biology Products: